Neuroscience

Beckley Psytech has dosed the first cohort of volunteers in a clinical trial exploring the safety of its novel formulation of intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT).  The Phase I study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of 5-MeO-DMT in psychedelic-naïve healthy subjects. This is the […]

A team of medical and pharmaceutical experts has founded SynaptixBio, an Oxford-based research company working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting condition. This is a sponsored research agreement with Children’s Hospital of Philadelphia (CHOP) in the US.  Antisense Oligonucleotides (ASOs) therapy, which has […]

Evotec has expanded its collaboration with Bristol Myers Squibb to include a new cell type.  The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is tremendous unmet medical need for […]

The brain: how much don’t we know? Dr Jim Ross, Chief Technology Officer and Co-founder of Axion BioSystems, asks and discusses the answers to this question. Epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s — we hear these brain disease names all the time, but it feels like we never hear about effective treatments or cures. While medical advances are gradually helping researchers understand the brain and address neurological […]

AlzeCure Pharma says its novel clinical candidate drug ACD440 for peripheral neuropathic pain is based on the seminal discoveries of TRPV1 by Professor David Julius, for which he was awarded the Nobel Prize in Medicine 2021.  Julius, Professor and Chair of the Department of Physiology and Morris Herzstein Chair in Molecular Biology and Medicine at UC San Francisco, has been […]

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves under the tongue for the acute, intermittent treatment […]

Register now for Neuroscience 2021, an SfN annual meeting where for the first time, the conference will have a hybrid format, featuring both virtual and in-person programming. A single registration fee will give attendees access to both formats.  Neuroscience 2021 will take place November 8 -11 virtually, and November 13-16 at McCormick Place Convention Center, in Chicago, […]

New research has moved a step forward in understanding how glucocorticoid hormones (‘stress hormones’) act upon the brain and what their function is. The findings could lead to more effective strategies in the prevention and treatment of mental health disorders. The study, led by academics at the University of Bristol and published in Nature Communications, […]

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel drug development strategy, leveraging digital […]

Scientists have successfully treated flies displaying behavioural problems linked to newly discovered schizophrenia-associated genes in humans, using common anti-psychotics. Schizophrenia is a severe long-term mental health condition that is historically poorly understood and treated. It is relatively common, affecting 1-2% of the population, and is known to be up to 80% genetic in origin. Recent […]